The stock of NeuBase Therapeutics Inc. (NASDAQ:NBSE) last traded at $0.20, up 2.60% from the previous session.
Data from the available sources indicates that NeuBase Therapeutics Inc. (NASDAQ:NBSE) is covered by 2 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $0.20, this indicates a potential upside of 4900.0 percent. NBSE stock price is now -15.30% away from the 50-day moving average and -60.83% away from the 200-day moving average. The market capitalization of the company currently stands at $6.87M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
In total, 2 analysts have assigned it a hold rating, and 0 have given it a buy rating. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target enhanced from $15 to $18, H.C. Wainwright maintained Buy rating for NeuBase Therapeutics Inc. (NASDAQ: NBSE). On June 16, 2020, RBC Capital Mkts recently initiated its ‘Outperform’ rating on the stock quoting a target price of $16, while ‘Guggenheim’ rates the stock as ‘Buy’.
In other news, Mann William Roland, Chief Operating Officer bought 6,200 shares of the company’s stock on Mar 30. The stock was bought for $11,904 at an average price of $1.92. Upon completion of the transaction, the Chief Operating Officer now directly owns 11,200 shares in the company, valued at $2240.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 18, Chief Financial Officer Branning Todd P. bought 10,000 shares of the business’s stock. A total of $18,100 was incurred on buying the stock at an average price of $1.81. This leaves the insider owning 30,000 shares of the company worth $6000.0. A total of 2.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBSE stock. A new stake in NeuBase Therapeutics Inc. shares was purchased by ERGOTELES LLC during the first quarter worth $8,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $8,000 in shares of NBSE during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in NeuBase Therapeutics Inc. valued at approximately $3,000. RITTER DANIHER FINANCIAL ADVISORY LLC / DE acquired a new stake in NBSE for approximately,000. In total, there are 49 active investors with 37.20% ownership of the company’s stock.
With an opening price of $0.1900 on Tuesday morning, NeuBase Therapeutics Inc. (NASDAQ: NBSE) set off the trading day. During the past 12 months, NeuBase Therapeutics Inc. has had a low of $0.17 and a high of $2.08. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 8.40, and a quick ratio of 8.40. The fifty day moving average price for NBSE is $0.2449 and a two-hundred day moving average price translates $0.5018 for the stock.
The latest earnings results from NeuBase Therapeutics Inc. (NASDAQ: NBSE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.24, beating analysts’ expectations of -$0.28 by 0.04. This compares to -$0.24 EPS in the same period last year. The company reported revenue of $4.6 million for the quarter, compared to $7.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -37.03 percent.
NeuBase Therapeutics Inc.(NBSE) Company Profile
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
